Viatris (XSWX:VTRS) Cyclically Adjusted Revenue per Share: CHF17.21 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:VTRS Viatris Inc XSWX:VTRS
63 GF Score
Price CHF13.19
GF Value CHF9.27
! 8 Warning Signs
View Full Analysis

What is Viatris Cyclically Adjusted Revenue per Share?

Viatris XSWX:VTRS -0.50% 63 Cyclically Adjusted Revenue per Share is CHF17.21 as of Jun. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 63/100 and a GF Value™ of CHF9.27. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Viatris's adjusted revenue per share for the three months ended in Jun. 2026 was CHF2.581. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF17.21 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Viatris's average Cyclically Adjusted Revenue Growth Rate was -3.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Viatris was 27.20% per year. The lowest was -2.60% per year. And the median was 12.50% per year.

As of today (2026-08-16), Viatris's current stock price is CHF13.188. Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was CHF17.21. Viatris's Cyclically Adjusted PS Ratio of today is 0.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 2.97. The lowest was 0.35. And the median was 0.70.


Viatris  (XSWX:VTRS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viatris's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.188/17.21
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 2.97. The lowest was 0.35. And the median was 0.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Viatris Cyclically Adjusted Revenue per Share Related Terms


Viatris Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Viatris's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Cyclically Adjusted Revenue per Share Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viatris Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 16.58 17.21

XSWX:VTRS vs UTHR, NBIX, ELAN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PS Ratio falls into.


XSWX:VTRS
63GF Score
Viatris Inc XSWX:VTRS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viatris's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.581/333.9520*333.9520
=2.581

Current CPI (Jun. 2026) = 333.9520.

Viatris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.682 241.428 7.860
201612 6.210 241.432 8.590
201703 5.073 243.801 6.949
201706 5.340 244.955 7.280
201709 5.354 246.819 7.244
201712 5.966 246.524 8.082
201803 4.924 249.554 6.589
201806 5.385 251.989 7.137
201809 5.366 252.439 7.099
201812 5.912 251.233 7.859
201903 4.848 254.202 6.369
201906 5.465 256.143 7.125
201909 5.684 256.759 7.393
201912 6.037 256.974 7.845
202003 4.860 258.115 6.288
202006 5.024 257.797 6.508
202009 5.252 260.280 6.739
202012 3.768 260.474 4.831
202103 3.411 264.877 4.301
202106 3.438 271.696 4.226
202109 3.452 274.310 4.203
202112 3.306 278.802 3.960
202203 3.211 287.504 3.730
202206 3.282 296.311 3.699
202209 3.259 296.808 3.667
202212 2.957 296.797 3.327
202303 2.863 301.836 3.168
202306 2.932 305.109 3.209
202309 2.937 307.789 3.187
202312 2.741 306.746 2.984
202403 2.691 312.332 2.877
202406 2.849 314.175 3.028
202409 2.647 315.301 2.804
202412 2.636 315.605 2.789
202503 2.412 319.799 2.519
202506 2.483 322.561 2.571
202509 2.570 324.800 2.642
202512 2.560 324.054 2.638
202603 2.356 330.213 2.383
202606 2.581 333.952 2.581

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF17.21 mean?
Viatris (XSWX:VTRS) has a Cyclically Adjusted Revenue per Share of CHF17.21 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viatris and its competitors.
Is Viatris' Cyclically Adjusted Revenue per Share too high?
Viatris' current Cyclically Adjusted Revenue per Share is CHF17.21. Overall, Viatris has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Cyclically Adjusted Revenue per Share compare to UTHR and NBIX?
Viatris' Cyclically Adjusted Revenue per Share of CHF17.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viatris and its competitors. Viatris's current Cyclically Adjusted Revenue per Share is CHF17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Cyclically Adjusted Revenue per Share of CHF17.21. The stock's GF Value™ is CHF9.27, compared to a current price of CHF13.19 — trading 42.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF17.21. Viatris' overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Cyclically Adjusted Revenue per Share is CHF17.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.19 is trading 42.3% above its estimated GF Value™ of CHF9.27.

Key valuation signals for XSWX:VTRS:

  • Cyclically Adjusted Revenue per Share: CHF17.21
  • GF Value™: CHF9.27 vs. price of CHF13.19 (42.3% above fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
63GF Score

Get the complete analysis for XSWX:VTRS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.19
Price
CHF9.27
GF Value